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The clinical success of allogeneic T cell therapy for cancer relies on the selection of antigens that can effec-
tively elicit antitumor responses with minimal toxicity toward nonmalignant tissues. Although minor his-
tocompatibility antigens (MiHA) represent promising targets, broad expression of these antigens has been
associated with poor responses and T cell dysfunction that may not be prevented by targeting MiHA with
limited expression. In this study, we hypothesized that antitumor activity of MiHA-speciﬁc CD8 T cells after
allogeneic bone marrow transplantation (BMT) is determined by the distribution of antigen relative to the site
of tumor growth. To test this hypothesis, we utilized the clinically relevant male-speciﬁc antigen HY and
studied the fate of adoptively transferred, HY-CD8þ T cells (HY-CD8) against a HY-expressing epithelial tumor
(MB49) and pre-B cell leukemia (HY-E2APBX ALL) in BMT recipients. Transplants were designed to produce
broad HY expression in nonhematopoietic tissues (female/ male BMT, [F/M]), restricted HY expression in
hematopoietic tissues (male/ female BMT, [M/F]) tissues, and no HY tissue expression (female/ female
BMT, [F/F]). Broad HY expression induced poor responses to MB49 despite sublethal graft-versus-host
disease and accumulation of HY-CD8 in secondary lymphoid tissues. Antileukemia responses, however,
were preserved. In contrast, restriction of HY expression to hematopoietic tissues restored MB49 responses
but resulted in a loss of antileukemia responses. We concluded that target alloantigen expression in the same
compartment of tumor growth impairs CD8 responses to both solid and hematologic tumors.
 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
The curative potential of allogeneic hematopoietic stem
cell transplantation (AlloHSCT) lies partly in the reactivity of
donor T cells against mismatched recipient antigens. The
infusion of allogeneic T cells is a potent form of immuno-
therapy and has been shown to cure relapsed leukemia [1,2].
Obstacles to the success of this approach have included weak
responses to solid tumors [3,4] and certain leukemias [5], as
well as challenges separating graft-versus-host (GVHD) from
graft-versus-tumor (GVT) effects [6]. The success of this
approach requires prudent selection of immunogenic target
antigens that produce effective antitumor responses while
sparing immune-mediated damage to host tissues.
Minor histocompatibility antigens (miHA) are promising
therapeutic targets because they do not require identiﬁca-
tion of tumor-speciﬁc epitopes, and they may be less sus-
ceptible to tolerance [7]. Targeting MiHA with adoptively
transferred T cells has been shown, preclinically, to eradicateedgments on page 35.
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13.10.009solid and hematologic malignancies [8,9]. Further, durable
GVT responses have been generated, with relative sparing of
GVHD, by immunizing donors against miHA before adoptive
transfer [10]. A potential pitfall of this approach, however, is
the generation of T cell dysfunction produced by broad
expression of minor antigens in alloHSCT recipients. Indeed,
expression of a target MiHA in nonhematopoietic tissues has
been shown to substantially reduce the efﬁcacy of adoptively
transferred T cells against solid tumors [11]. Proposed
mechanisms for this phenomenon include chronic and
inefﬁcient antigen presentation [12], blockade of functional
CD8 memory [13], induction of donor T cell apoptosis [14],
and upregulation of negative costimulatory molecules, such
as PD-1 [15]. Although these studies have established the
inﬂuence of minor antigen distribution on the potency of
adoptively transferred T cells, the relationship between tis-
sue antigen expression, site of tumor growth, and T cell
function has not been directly studied in a single antigen
system.
In the present study, we adoptively transferred miHA-
speciﬁc T cells into alloHSCT recipients mismatched at the
male-speciﬁc minor antigen HY, expressed on either non-
hematopoietic or hematopoietic tissues, and assessed their
antitumor efﬁcacy against an HY-expressing epithelial tumor
and leukemia.We selected HYas a target antigen because it is
endogenous, MHC-restricted, and has been implicated in
clinically signiﬁcant GVHD and GVT effects [16,17]. We
demonstrate that broad HY expression produces poorTransplantation. Published by Elsevier Inc. All rights reserved.
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matopoietic restriction of HY. Antileukemia responses,
however, are lost with hematopoietic restriction of HY and
preserved with broad expression, suggesting that the prox-
imity of target antigen expression to the site of tumor growth
predicts the efﬁcacy of adoptively transferred T cells during
alloHSCT.
MATERIALS AND METHODS
Mice
C57BL/6 (B6) CD45.1 (H-2b congenic) mice were purchased directly from
the National Cancer Institute-Frederick Animal Production Program (Fred-
erick, MD) via the Jackson Laboratories (Bar Harbor, ME). MataHari (B6
Rag1/, CD8þ TCRTg, H2-Db-restricted, CD45.2þ) mice [18] were used to
generate T cells for adoptive transfer and purchased from the NIAID-Taconic
repository (Rockville, MD). All animals were cared for under an animal use
protocol reviewed and approved by the National Cancer Institute Laboratory
Animal Safety Program-Animal Care and Use Committee (Bethesda, MD).
T Celledepleted Bone Marrow Transplantation
Bone marrow cells were ﬂushed from the tibias and ﬁbulas of female or
male B6 CD45.1þ mice using 10% complete mouse media CMM; RPMI 1640
with 10% heat-inactivated fetal calf serum, 1% nonessential amino acids, 1%
sodium pyruvate, 1% penicillin/streptomycin, 1% l-glutamine (Invitrogen,
Carlsbad, CA) and 1% N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
buffer (Sigma-Aldrich, St. Louis, MO), passed through a 70-um nylon ﬁlter,
and erythrocyte depleted using ACK lysis buffer (Lonza Walkersville, Wal-
kersville, MD). T cells were depleted from donor marrow using anti-CD3
microbeads through automated magnetic cells sorting (AutoMACS, Milte-
nyi Biotec, Auburn, CA). 3.5  106 T celledepleted marrow was injected in
serum-free RPMI via tail vein injection into recipients that were adminis-
tered lethal irradiation at a dose of 1100 cGy (137 Cs source) on the same day.
Female or male B6 CD45.1þ HSCT recipients were weighed twice every
7 days. Clinical monitoring for GVHD, including observation for skin
changes, fur changes, hunched posture, and mobility was performed daily
according to an established scoring system [19]. We have previously
demonstrated GVHD in additional target organs, including the liver, in male
recipients of HY-speciﬁc CD8 donor lymphocyte infusion [20].
Adoptive Transfer and Detection of HY-speciﬁc CD8þ T Cells
Single cell suspensions of splenocytes from naïve female MataHari do-
nors were prepared and 1  107 splenic CD8þ T cells were intravenously
injected on day 7. The delayed adoptive transfer platform was selected to
allow engraftment of donor antigen presenting cells and leukemic cells [21].
Detection of HY-CD8 was performed by ﬂow cytometry in the spleen and
bone marrow of mice either euthanized at speciﬁc weekly time points or for
disease-related morbidity by gating on live, CD8aþCD45.2þ cells. This was a
reliable gating strategy because splenocytes from HY-TCR transgenic donors
contain negligible numbers of CD8aþ myeloid cells and donor CD8 recon-
stituted from the T celledepleted transplant would not express the congenic
marker CD45.1. Absolute numbers of HY-CD8 were determined per 100,000
live-gated events. If more than 100,000 events were collected, the absolute
number of cells was normalized to 100,000 by the proportion
(#CD8aþCD45.2þ/total live cells ¼ [x/100,0000]).
Ex vivo Sorting and HY Peptide Stimulation of HY-speciﬁc CD8þ T Cells
Single cell suspensions of bone marrow were prepared as described
above and stained with ﬂuorochrome-conjugated anti-CD8a and CD45.2
antibodies to identify adoptively transferred HY-CD8 for ﬂow cytometry-
based sorting. Live, CD8aþCD45.2þ were sorted in PBS/.1% BSA in sterile
conditions on an LSRII ﬂow cytometer (BD Biosciences). Immediately after
sorting, proliferation to HY-peptide stimulation was measured using car-
boxyﬂuorescein diacetate succinimidyl ester (CFSE) dilution and ﬂow
cytometry. Sorted cells were washed twice in PBS/.1% BSA, labeled with
5 uM CFSE (Molecular Probes, Eugene, OR) for 10 minutes at 37C, placed in
culture at a concentration of 1  106 cells/ml CMM, and stimulated with
100 uM UTY peptide (Class I Dominant HY peptide, WMHHNMDLI) for
72 hours at 37C. Cells were then harvested, washed twice in FACS buffer,
and prepared for ﬂow cytometry.
Dendritic Cell Vaccination
Dendritic cells used for vaccines were cultured from male B6 bone
marrow as previously described [22]. Dendritic cells were activated with
4 mg/mL anti-CD40 on day 8, collected within 24 hours of activation,
resuspended in serum-freemedia, and intraperitoneally injected at a dose of
1  105 cells per recipient at the time of adoptive CD8þ T cell transfer.MB49 Tumor Challenge
The MB49 cell line was originally provided by Dr. Edmund Lattime
(Robert Wood Johnson Medical School, New Brunswick, NJ). MB49 is a
chemically induced uroepithelial carcinoma that expresses the male-
speciﬁc HY minor antigen [23] and is B6-derived. MB49 was maintained
in standard sterile culture conditions (37C, 5% CO2) in CMM. Exponentially
growing tumor cells were harvested with trypsin and injected at a dose of
1  106 cells per recipient into the subcutaneous tissue of the left ﬂank.
Tumors were measured in 2 dimensions (lengthwidth) twice every 7 days
by digital caliper. Approximate spherical volumes were calculated for each
measurement according to (length/2)  (width/2)  (length þ width/
4) (4p/3). Micewere euthanized with C02 when tumor diameters 2.0 cm
or tumor-relatedmorbidity developed according to institutional protocols. If
a mouse was euthanized or found dead, the most recent tumor measure-
ment was carried forward for the remainder of the experiment.
Pre-B Cell Acute Lymphoblastic Leukemia Challenge
A male, GFP-conjugated, B6-derived murine pre-B cell acute lympho-
blastic leukemia cell line carrying the human E2a-PBX1 transgene by MMLV
insertion as previously described [24] was generously provided by Dr. Janet
Bijil (Centre de Recherche de l’Hopital Maisonneuve-Rosemont, Montreal,
Quebec, Canada). Cells were maintained in culture at 37C and 5% CO2,
harvested on day 3 in an early exponential growth phase, and prepared as
single-cell suspensions. 5  105 leukemia cells were infused by tail vein
injection in serum-free RPMI at the time of bone marrow transplantation
(BMT). Monitoring for leukemia-related morbidity, including hind leg pa-
ralysis, wasting, abdominal distention, and poor movement, was performed
daily. Leukemia burden in the bone marrow and spleen was measured by
ﬂow cytometry in animals euthanized at speciﬁc time points or for
leukemia-associated morbidity. Animals with clinical ﬁndings suggestive of
leukemia morbidity but with no GFP þ cells in the marrow were censored
from leukemia survival analysis.
HY-speciﬁc Immunogenicity of Male E2a-PBX ALL by Interferon Gamma
ELISA
HY-speciﬁc immunogenicity of male E2APBX-ALL was established by
coculturing male E2a-PBX ALL, female E2a-PBX ALL with positive control
male dendritic cells with HY-CD8 for 72 hours at a stimulator to responder
ratio of 1 (1 106):1 (1106). Concentrations of IFN-y (pg/mL) from in vitro
cocultures were measured by ELISA (Quantikine IFN-y, R&D Systems) in
triplicate according to the manufacturer’s protocol and read at 450 nm on a
microplate reader (BioRad, Hercules, CA).
Flow Cytometry
FACS analysis for surface molecule expression was performed on an LSR
II Fortessa ﬂow cytometer (BD Biosciences, Hunt Valley, MD). The following
monoclonal antibodies were utilized for ﬂow-cytometry: ﬂuorescein iso-
thiocyanate, phycoerythrin, peridinin chlorophyll protein complex, cyanine
5.5 (PerCP-Cy 5.5), allophycocyanin, and Paciﬁc Blueeconjugated anti-
mouse B220, CD4, CD8a, CD44, CD45.2, CD62L, PD-1 and Tim-3. Compen-
sation controls and immunoglobulin isotype controls were generated for
each experiment using fresh splenocytes.
Statistical Analysis
Statistical tests were performed using GraphPad Prism version 4.0b for
MacIntosh (GraphPad Software, San Diego, CA). For tumor volume mea-
surements, the last tumor volume recorded for each mouse at the time of
death was used in calculations of tumor volume at each time point after
death. Kaplan-Meier survival curves were created and analyzed using the
Wilcoxon rank-sum test to analyze curves. Signiﬁcant differences between
groups in clinical scores, in vivo T cell enumeration, and in vitro assays were
determined by unpaired Student t-test. P values less than .05 were consid-
ered signiﬁcant.
RESULTS
Broad HY Expression in Nonhematopoietic Tissues,
Expands Adoptively Transferred HY-CD8 in Secondary
Lymphoid Tissues and Produces GVHD
We ﬁrst established whether HY mismatch was sufﬁcient
to produce clinically signiﬁcant alloreactivity in our model.
Critical to this objective was the ability to enumerate and
track antigen-speciﬁc CD8 as a function of HY tissue distri-
bution in alloHSCT recipients with sublethal GVHD. Although
HY mismatch has been associated with lethal GVHD when
HY-CD8 are infused at the time of alloHSCT [25], we have
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quantitative analysis of T cell responses using a delayed
infusion platform [26]. In this study, B6 male and females
received T celledepleted B6 female BMT ([F/M] and [F/F]
respectively) on day 0, followed by adoptive transfer of
1  107 MataHari (HY-CD8) on day 7. Clinical GVHD scoring
and enumeration of HY-CD8 was performed through
day þ35 to 42 post-BMT. As expected, adoptive transfer of
HY-CD8 produced a nonlethal, clinical GVHD in males as
deﬁned by clinical score (Figure 1A). HY-directed GVHD in
this model manifested primarily with skin changes (scaling,
denuded areas), fur changes (rufﬂing, patchy loss) and
decreased activity (Figure 1B) consistent with other murine
models of single minor antigen-mismatch alloHSCT [20,27].
Broad expression of HY in [F/M] recipients resulted in the
accumulation of large numbers of, CD8aþCD45.2þHY-CD8, in
both the spleen and bone marrow (Figure 1C). As expected,Figure 1. Adoptively transferred HY-speciﬁc CD8 T-cells expand and produce GVHD in
depleted marrow on day 0, followed by 1  107 HY-speciﬁc CD8 by tail vein injection
GVHD scores on day þ60 after transplantation were consistent with sublethal GVHD, p
activity, compared with no clinical signs of GVHD in syngeneic female recipients of fe
10 mice/group. (C) HY-speciﬁc CD8 were enumerated from spleen and bone marrow o
(day þ14 and þ35 post BMT) by gating on live, CD8aþCD45.2þ cells. Representative
splenocytes (right panel, top) or bone marrow cells (left panel, bottom) are shown.syngeneic female controls with no tissue expression of HY
had low but detectable numbers of HY-CD8. Four weeks after
adoptive transfer, signiﬁcantly higher numbers of HY-CD8
could still be detected in [F/M] recipients compared to
their [F/F] counterparts (Figure 1D).
Adoptively Transferred HY-CD8 Expand to Broad HY
Tissue Expression but Do Not Control a HY-expressing
Solid Tumor
Although vaccination against miHA has been shown to
cure solid tumors, we have previously observed reduced
tumor-speciﬁc vaccine responses when alloreactivity gener-
ated against minor antigens is not shared by the tumor
[20,26]. In the present study, we wished to determine how
CD8 function is affected by alloreactivity produced by an
antigen shared by the tumor. Again, [F/M] and [F/F]
T celledepleted BMT recipients were given 10  10e6 HY-allogeneic males. Lethally irradiated B6 male mice received 5  106 T cell (CD3)
on day þ7. Clinical GVHD scoring was performed once weekly. (A) Composite
articularly manifested as (B) changes in skin integrity, fur rufﬂing, and posture/
male BMT. GVHD scoring data represent 4 independent experiments with 6 to
f transplant recipients by ﬂow cytometry 7 and 28 days after adoptive transfer
ﬂow plots (left panel) and total numbers of CD8aþCD45.2þ cells per 100,000
Figure 2. Adoptively transferred HY-speciﬁc CD8 cannot control MB49 in male recipients. Experimental [F/M] and control [F/F] B6 mice received T celledepleted
B6 female bone marrow on day 0, followed by adoptive transfer of HY-CD8 on day þ7. They were then challenged with 1  105 MB49, an HY-expressing epithelial
tumor, subcutaneously on day þ14. Tumor-free survival was followed daily (A), and tumor volumes measured in 2 dimensions twice weekly (B). [F/M] recipients
(closed square, solid line) had poor tumor control, similar to [F/F] controls that did not receive HY-CD8 (dotted line, closed triangle). [F/F] recipients of HY-CD8
preserved immune responses. (C) Enumeration of adoptively transferred HY-CD8 in spleen as live, CD8aþCD45.2þ cells 14 days after adoptive transfer showed
signiﬁcant accumulation of HY-CD8 in [F/M] despite poor tumor control, compared to [F/F] tumor bearing (closed circle) or tumor-free recipients. (D) Expression
of PD-1 (gray shaded) compared to IgG2k isotype controls (black dotted) was measured on live, CD8þCD45.2þ HY-speciﬁc CD8 on day þ14 post BMT (at the time of
MB49 injection) by ﬂow cytometry. Expansion data and PD-1 histograms are representative of at least 4 independent experiments with 6 to 10 mice/group. (E) Live,
CD8þCD45.2þ cells were collected by ﬂow sorting on day þ14 post BMT and restimulated in vitro with the Class I immunodominant HY peptide (UTY). Proliferation
was measured by CFSE dilution at 72 hours. Naïve female MataHari (HY-speciﬁc) splenocytes served as controls.
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MB49, an immunogenic [28] HY-expressing uroepithelial
tumor, on day þ14. [F/M] that did not receive HY-speciﬁc
adoptive transfer served as controls. All [F/M] mice devel-
oped rapidly growing tumors, with 100% tumor-associated
mortality by day þ35 post-tumor injection (dayþ42 post
BMT) (Figure 2A,B). This survival curve was statistically
identical to [F/M] that did not receive HY-CD8. [F/F] re-
cipients of HY-CD8 adoptive transfer; however, they
demonstrated preserved antitumor responses with
55  3.7% tumor-free survival (P < .0035). [F-/F] that
developed tumors did so at a signiﬁcantly slower rate
(P ¼ .039) and had longer overall survival, suggesting
improved tumor control (Figure 2B).
Enumeration of CD8 þ CD45.2þ HY-CD8 in the spleen on
day þ21 post-tumor injection (day þ42 post BMT) was per-
formed on [F/M] and [F/F] that developed tumors and
[F/F] tumor-free survivors in a cohort not included in sur-
vival analysis. This time point was selected because it rep-
resented both the point of accelerating tumor growth and
robust HY-CD8 accumulation in the GVHD studies. Signiﬁ-
cantly more HY-CD8 accumulated in the spleen (Figure 2C,
representative ﬂow plots left panel, total number of HY-CD8
right panel) of [F/M] recipients, compared with syngeneic
[F/F] recipients that developed tumor (P ¼ .0042). [F/F]
tumor-free survivors had signiﬁcantly higher numbers of HY-
CD8 than their tumor-bearing counterparts, suggesting that
adoptively transferred HY-CD8 could expand in response to
MB49 and were not deleted in the short term. Interestingly,
100% of HY-CD8 recovered from the spleen of [F/M] re-
cipients expressed PD-1, wheras [F/F] did not express PD-1,
regardless of whether they were able to control tumor
(Figure 2D).
Poor survival, rapid tumor growth, and PD-1 expression
suggested that adoptively transferred CD8 became dysfunc-
tional in [F/M] mice where HY was broadly expressed. To
begin to investigate whether HY-CD8 could respond to HY
independent of the allogeneic environment, HY-CD8 were
isolated by ﬂow sorting live, CD8aþ CD45.2þ splenocytes on
day þ21 (dayþ14 postadoptive transfer). An increased HY-Figure 3. HY-expressing dendritic cell vaccination cannot restore antitumor response
tissues. Lethally irradiated female or male B6 recipients were transplanted with TCD f
activated male dendritic cells were injected intraperitoneally also on day þ7. AlloH
growth in [F/F] recipients (closed triangle, solid line) and [F/M] recipients (close
Unvaccinated [F/M] (closed square, dotted line) and [M/F] (closed triangle, dotted l
are representative of 3 independent experiments with 8 to 10 mice/group.CD8 dose of 5  107 was utilized to improve the sorted
yield. The time point selected corresponded to the day of
MB49 injection in tumor challenge studies. Sorted HY-CD8
and naive MataHari control splenocytes were placed in cul-
ture, stimulated ex vivo with the class I immunodominant
HY peptide UTY, and proliferation measured after 72 hours
by CFSE dilution. Under these conditions, both HY-CD8
recovered from [F/F] recipients and naïve HY-CD8 con-
trols proliferated, whereas HY-CD8 from [F/M] recipients,
did not (Figure 2E).
HY-expressing Dendritic Cell Vaccination Cannot Restore
Functionality of HY-CD8 Expanded by Broad HY
Expression
To determine whether professional HY antigen presen-
tation could overcome poor immune responses in [F/M]
recipients, 1  105 anti-CD40 activated male DCs were
injected intraperitoneally at the time of HY-CD8 adoptive
transfer on day þ7, followed by MB49 challenge on day þ14.
DC vaccination completely prevented tumor growth in
[F/F] recipients (100% tumor-free survival, Figure 3A),
whereas all of the [F/M] developed progressive tumors. As
expected, survival curves in unvaccinated controls receiving
HY-CD8 were consistent with those shown in Figure 2B.
Restriction of HY to Hematopoietic Tissues Preserves
Functionality of Adoptively Transferred HY-CD8 but Does
Not Prevent PD-1 Expression
To determine whether restricted expression of HY could
improve antitumor responses, we transplanted T cellede-
pleted B6 male marrow into female B6 mice [M/F] and
adoptively transferred HY-CD8 on day þ7 as described
before. No systemic GVHDwas observed in [M/F] recipients
of HY-CD8 (Figure 4A, top panel) and marrow cellularity was
similar at day þ60 to [F/M] (Figure 4A, bottom panel),
excluding an early immune-mediated aplasia.
When [M/F] were challenged with MB49 at day þ14
post-BMT, tumor-free survival was 52.5  4.9% (Figure 4B),
similar to [F/F] recipients shown in Figure 2A. Enumeration
of CD8aþCD45.2þ cells in [F/M], [M/F], and [F/F] froms in [F/M] recipients of HY-speciﬁc CD8 that express HY in nonhematopoietic
emale B6 bone marrow on day 0, 1 107 HY-CD8 on day þ7 and 1 105 CD40-
SCT recipients were then followed for (A) tumor-free survival and (B) tumor
d square, solid line), with rapidly growing tumors (closed square, solid line).
ine) that received HY-CD8 served as controls. Survival and tumor volume curves
Figure 4. Hematopoietic restriction of HY preserves responses to MB49 despite PD1 expression on adoptively transferred HY-speciﬁc CD8. To restrict HY to he-
matopoietic tissues, lethally irradiated female B6 mice received T celledepleted B6 male [M/F] BMT on day 0 followed by 1  107 HY-speciﬁc CD8 on day þ7.
AlloHSCT recipients were (A) clinically graded for GVHD and total bone marrow cells recorded after erythrocyte lysis to assess overall marrow cellularity. (B) Re-
cipients were next challenged with MB49 on dayþ14 and followed for tumor-free survival in [F/M] (closed square) and [M/F] (closed diamond) groups. Data show
a single experiment representative of 3 independent experiments with 8 to 12 mice/group. (C) Accumulation of HY-CD8 was measured by ﬂow cytometry as live,
CD8aþCD45.2þ cells 14 days after adoptive transfer via representative contour plots (left panels) and absolute numbers per 100,000 splenocytes (right, top panel) or
bone marrow cells (right, bottom panel). (D) PD-1 expression was measured by ﬂow cytometry on HY-CD8 in the spleen and bone marrow of [M/F] and [F/M]
recipients 14 days after adoptive transfer. Histograms depict live, CD8aþCD45.2þPD1þ cells (gray shaded) compared to IgG2k isotype controls (dashed line). Data
shown are representative of 3 independent experiments. (E) To verify functionality, HY-CD8 were sorted from [F/M] and [M/F] ex vivo 14 days after adoptive
transfer, restimulated with UTY peptide, and proliferation measured by CFSE dilution after 72 hours. (F) Expression of PDL-1 (B7:H1), the ligand for PD-1, was
measured by ﬂow cytometry in MB49 before subcutaneous injection (gray shaded) and at day þ28 in animals that succumbed to tumor-related mortality and shown
in this representative histogram.
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(7 days after adoptive transfer, 14 days after BMT) revealed a
similar accumulation of HY-CD8 in these tissues (Figure 4C).
However, 21 days after tumor challenge (dayþ42 after BMT),
there were signiﬁcantly higher numbers of HY-CD8 in the
spleen of [M/F] compared with [F/M] recipients, regard-
less of their ability to control tumor (Figure 4C, top panel).
Interestingly, numbers of HY-CD8 in the bone marrow
remained high in all groups, and were not statistically
different between groups (Figure 4C, bottom panel).
Unexpectedly, as shown in Figure 4D, PD-1 was uniformly
expressed on CD8aþCD45.2þ HY-CD8 recovered from the
spleen and bone marrow of tumor-bearing [F/M], tumor-
bearing [M/F], and tumor-free [M/F] (day 21 after tumorFigure 5. Hematopoietic restriction of HY does not preserve antileukemia response
murine, male, GFP-conjugated pre-B cell ALL (E2APBX-ALL) was determined by cocul
and measuring interferon gamma production by ELISA at 48 hours. Male dendritic
controls, respectively. (B) Overall survival was measured after 1  105 E2APBX-ALL cel
square), ([M/F], solid diamond) and ([F/F], solid circle) recipients on day 0, followe
(dotted line) served as negative controls. (C) The quantity of GFPþ cells in the bone m
time of death or dayþ72 post transplantation. (D) Number of bone marrow-inﬁltratin
transplantation and coinjection (intravenously) of 1  105 E2APBX-ALL cells. Data shchallenge, day þ42 after BMT), suggesting that PD-1 expres-
sion did not correlate with the ability to reject tumor. To
determine the ability of adoptively transferred HY-CD8 to
respondtoHYindependentof theallogeneicenvironment, live,
CD8aþCD45.2þ bone marrow cells were ﬂow sorted in a
separate experiment 14 days after adoptive transfer, placed in
culture, stimulated with UTY for 72 hours, and proliferation
measured by CFSE dilution. CD8aþCD45.2þ cells from [M/F]
bone marrow did proliferate, whereas those sorted from
[F/M] bone marrow did not (Figure 4E) indicating that bone
marrow expression of HY impaired the functionality of HY
speciﬁc T cells. PDL-1 (B7:H1), the ligand for PD-1, was not
expressed on MB49 either before injection or on established
tumors in mice (Figure 4F). Collectively, these results suggests, which are restored with broad expression of HY. (A) Immunogenicity of a
turing 1  106 male versus female E2APBX with 1  106 MataHari splenocytes
cells and naïve MataHari splenocytes alone served as positive and negative
ls were incorporated into T celledepleted intravenous grafts into ([F/M] solid
d by adoptive transfer of HY-CD8 on day þ7. [F/F] that did not receive HY-CD8
arrow was assessed by ﬂow cytometry to measure leukemia burden either at
g HY-CD8 (live, CD8þCD45.2þ) on day þ7, þ14 and þ21 after T celledepleted
own are representative of 3 independent experiments.
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required for loss of HY-CD8 tumor control and that PD-1
expression may instead represent a nonspeciﬁc activation
marker, perhaps because of T cell activating allogeneic effects.
HY Expression on Hematopoietic Tissues Results in Poor
Antileukemia Responses, despite Continued Expansion of
HY-CD8 in the Bone Marrow
We next determined whether hematopoietic restriction
of HY could also preserve antileukemia responses against a
GFP-conjugated, murine pre-B cell acute lymphoblastic leu-
kemia derived from male mice carrying the human E2A-PBX
transgene (E2APBX-ALL) [24]. To establish that this male-
derived E2APBX-ALL cell line expressed immunologically
signiﬁcant HY, we cocultured HY-CD8 for 72 hours with male
or female E2APBX-ALL in a 1:1 ratio and measured
interferon-gamma production by ELISA. Coculture of HY-CD8
with female E2APBX-ALL did not produce detectable inter-
feron gamma levels, whereas coculture with male E2APBX-
ALL resulted in substantial interferon gamma production at
72 hours (607  26.1 pg/mL, P ¼ .0019, Figure 5A). This
conﬁrmed HY-speciﬁc immunogenicity of the male E2APBX-
ALL cells for incorporation into the alloHSCT model.
For the leukemia challenge study, 1  105 male E2APBX-
ALL were injected intravenously at the time of T cellede-
pleted BMT on day 0 into [F/M], [M/F], and [F/F] re-
cipients, followed by adoptive transfer of 1 107 HY-CD8 on
day þ7. GFPþ leukemia burden in the bone marrow was
assessed postmortem by ﬂow cytometry. In contrast to the
solid tumor model, [M/F] recipients suffered 100%
leukemia-associatedmortality by dayþ25 post BMT, at a rate
identical to [M/F] recipients that did not receive HY-CD8
adoptive transfer (Figure 5B). [F/M] recipients, on the
other hand, had 82.1% 5.8% leukemia-free survival. As in the
solid tumor model, [F/F] recipients also preserved anti-
leukemia responses after adoptive transfer of HY-CD8, with
62%5.2% survival. Leukemia-associatedmortality in [M/F]
recipients was characterized by massive splenomegaly and a
high burden (64.8%  9.7%) of GFPþ leukemia in the bone
marrow (Figure 5C) measured by ﬂow cytometry at the time
of death. [F/M] survivors had no or very low levels of
detectable leukemia on day þ72 post BMT (.11%  0.83%),
whereas [F/F] recipients had low levels of leukemia, with
2.2%  1.7% GFPþ cells in the marrow (Figure 5C). Achieve-
mentof leukemia control bydayþ21 in [F/M]recipientswas
associatedwith a contraction of theHY-CD8 population in the
bonemarrow (Figure 5D) compared to persistence of HY-CD8
in [M/F] with poor leukemia control. In contrast to the solid
tumor model, leukemia challenge was sufﬁcient to expand
HY-CD8 in [F/F] recipients, though to a lesser degree.
Restoration of Leukemia Control by Broad HY Expression
is Associated with a Loss of PDL-1 Expression on
Leukemia Cells, despite Continued Expression of PD-1 on
Marrow-inﬁltrating HY-CD8
Next, we determined the PD-1 expression status of bone
marrow inﬁltrating HY-CD8 after leukemia challenge fromFigure 6. Expression of PDL-1 on leukemia cells, but not PD-1 on HY-CD8, correlates w
of HY-speciﬁc CD8 (live, CD8þCD45.2) that were also PD1þ was measured by ﬂow
[F/M], [M/F] and [F/F] recipients that simultaneously received 1  105 E2APBX-A
isotype controls was measure on live, CD8þCD45.2þ cells from the bone marrow was m
panels). Data shown are representative of 2 independent experiments. (B) Percentage
by ﬂow cytometry on day þ7, þ14, and þ21 post transplantation and leukemia challe
intensity on day þ7 (dotted lines) and þ14 (solid lines) are also shown. A contour plots
ALL in the bone marrow is shown to the far right. Data shown are representative ofthe time of engraftment (day þ7) to the time of either leu-
kemia progression (in [M/F]) or control (in [F/M] and
[F/ F]). Despite good antileukemia control and contraction
of the HY-CD8 pool in [F/M] recipients, nearly 100% of HY-
CD8 expressed PD-1 (Figure 6A, top row), and 43.7  4.8 of
PD-1þ cells coexpressed the negative costimulatory receptor
Tim-3, required for PD-1 induced CD8 exhaustion in some
models [29]. In [M/F] recipients, where leukemia control is
poor, HY-CD8 maintained high levels of PD-1 expression
(Figure 6A, center row) until the time of leukemia-associated
death. Unexpectedly, by this time, HY-CD8 had lost their PD-
1 expression and did not coexpress Tim-3. [F/F] recipients
expressed PD-1 in a high percentage of their cells early in
engraftment (day þ7). Although some [F/F] lost PD-1
expression by day þ21, this did not correlate with loss or
gain of leukemia control (data not shown) as in the setting of
HY allogeneic mismatch.
Finally, we determined whether PD-1 ligand (PDL-1, or
B7:H1) expression on HY-E2APBX leukemia cells correlated
with maintenance or loss of PD-1 expression on HY-CD8. In
2 independent experiments, we observed that as leukemia
control is achieved in [F/M] recipients, PDL-1 expression on
live HY-E2APBX leukemia cells is lost, despite continued
expression of PD-1 on HY-CD8. Conversely, as leukemia
control is lost in [M/F] recipients, the number of HY-
E2APBX leukemia cells expressing PDL-1 increases, despite
loss of PD1 expression on HY-CD8.
DISCUSSION
Endogenous miHA remain ideal targets for adoptive
immunotherapy because of their physiologic expression
levels compared with antigens generated, or targeted, by
exogenous gene modiﬁcation. Because most miHA are not
tumor speciﬁc, we hypothesized that the antitumor reac-
tivity of T cells to endogenous antigens is directly affected by
the relative expression of that antigen in malignant and
nonmalignant tissues. The degree to which the pattern of
nonmalignant tissue antigen expression impacts the func-
tionality of miHA-directed responses against tumors that
might share the antigen directly impacts which candidate
antigens should be selected for adoptive therapy in the clinic.
The ability of an experimental system to answer these
questions preclinically required (1) controlling the degree of
nonmalignant tissue miHA expression; (2) availability of
T cells speciﬁc for that miHA; and (3) tumors that endoge-
nously express the miHA and are capable of eliciting miHA-
speciﬁc responses. We devised an experimental system
that satisﬁed these criteria, based on mismatch at the minor
alloantigen complex HY.
The male minor antigen complex HY was selected as the
modelmiHA in this system because it has beenwell validated
as a clinically relevant minor antigen in allogeneic trans-
plantation, capable of generatingbothGVHDandGVL [30].HY
disparity represents a mismatch at multiple genes, rather
than a singleMHC-associated locus, and thusmay represent a
more physiologic, and translatable, approach to antigen
mismatch than artiﬁcially gene deﬁcient mice [31]. Inith improved leukemia control when HY is broadly expressed. (A) The percent
cytometry at day þ7, þ14, and þ21 after T celledepleted transplantation into
LL cells on day 0. PD-1 and Tim-3 expression (gray shaded) compared to IgG2k
easured by ﬂow cytometry at either study endpoint or at the time of death (left
of total GFPþB220þ E2APBX-ALL expressing PDL1 (right panels) was measured
nge (center panels). Representative histograms comparing PDL-1 ﬂuorescence
showing the gating strategy for identiﬁcation of live, B220þGFPþ HY-E2APBX-
2 independent experiments.
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dominant peptide complex is known, in mice and in humans,
forwhichwe, and others, have generated clinically signiﬁcant
immune responses against tumors thatendogenouslyexpress
HY [18,28]. Although we recognize that because of the sex-
speciﬁc expression of HY there are clinical scenarios in
which our data cannot be directly extrapolated, for example,
the occurrence of amale/HYeexpressing leukemia in a female
recipient, these scenarios were required as experimental
controls to isolate the key determinants of antigen-speciﬁc
T cell responses as a function of minor antigen distribution.
Our observations based on this model, for example, that he-
matopoietic restriction of a miHA may induce local CD8
dysfunction and may not represent an ideal target antigen,
can certainly be extrapolated to the selection of other miHA
complexes being considered for therapeutic use.
We speciﬁcally observed that broad expression of HY in
nonhematopoietic tissues produces poor responses to an HY-
expressing solid tumor and is associated with signiﬁcant
accumulation of adoptively transferred HY-speciﬁc CD8 in
secondary lymphoid tissues that express PD-1. This was not
surprising, given the growing body of evidence that chronic,
high levels of viral [32-34] or alloantigen [35] presentation
can produce T cell dysfunction. This observation is also
consistent with reports by Meunier et al. [11] that broad
tissue expression of minor antigens can generate large
numbers of dysfunctional CD8 that are more susceptible to
apoptosis. Although our data show that these cells persist in
relatively stable numbers 4 weeks after adoptive transfer, the
fact that they cannot respond to repeat antigen stimulation
ex vivo suggests a more terminal dysfunction that is not
entirely dependent on the allogeneic environment. Further,
our model indicates that professional HY antigen presenta-
tion in the form of an activated DC vaccine cannot overcome
these effects, an observation that has clinical relevance for
the incorporation of antigen-speciﬁc cancer vaccines into
alloHSCT regimens.
Targeting hematopoietically restricted minor antigens
has been proposed as an ideal strategy to optimize graft-
versus-tumor effects while sparing systemic GVHD [7,36].
Asakura et al. have shown that GVT effects are augmented
when target minor antigens are hematopoietically restricted
and can reverse poor responses induced by T cells exposed to
broadly expressed minor antigens [14]. In addition, Li et al.
have demonstrated that adoptive transfer of memory CD8
from donors vaccinated against a restricted miHA can
enhance GVT effects [10]. On this basis, we reasoned that
hematopoietic restriction of HYmight also improve poor HY-
CD8 responses to MB49. Indeed, responses to MB49 were
partially restored and HY-CD8 retained the ability to prolif-
erate to HYex vivo, despite continued expression of PD-1. We
were able to preserve CD8 activity to a restricted miHA
without prior donor vaccination, suggesting that prudent
selection of minor antigens alone may maximize the beneﬁt
of adoptively transferred allogeneic T cells without addi-
tional manipulations to the donor.
Restoration of responses to MB49 led us to question
whether restriction of HY to hematopoietic tissues would
also confer superior antileukemia responses. However, GVT
effects were profoundly reduced in this setting despite
continued presence of HY-CD8 in the bone marrow and loss
of PD-1 expression, compared with superior responses when
HY was broadly expressed. We, therefore, concluded that
expression of a shared minor antigen in the same tissue
compartment as the tumor (nonhematopoietic for solidtumors, hematopoietic for leukemia) predicts poor GVT re-
sponses. Conversely, minor antigens expressed outside the
primary tumor compartment (hematopoietic for solid tu-
mors, nonhematopoietic for leukemia) produced durable
GVT responses.
In our model, this location-speciﬁc pattern of antigen
expression was the primary determinant of antitumor CD8
activity, rather than degree of clinical GVHD, expansion
of adoptively transferred T cells or expression of PD-1.
Although PD-1 has most recently been associated with
T cell dysfunction and immune regulation, it has also been
described as a marked of T cell activation [37,38] and we
would expect HY-speciﬁc CD8 to be activated in the setting of
HY-directed alloreactivity. The fact that PD-1 is not expressed
on CD8þ Tcells in the setting of poor antileukemia responses
suggests that PD-1 biology may be uniquely modulated
when alloimmunity is localized to a leukemia-bearing
marrow environment.
Teshima et al. recently observed that PD-1 blockade
partially reverses GVL suppression induced by epithelial
expression of alloantigen and subsequent CD8 exhaustion
and apoptosis [14]. These work is complemented by the
observation by Schlomchik et al. that PD-1 expression is
increased on effector memory (but not central memory) CD8
capable of tissue homing and expansion but not sustained
GVHD or interferon production, suggesting a repertoire-
independent functional defect in these cells, transgenic for
a ubiquitously expressed minor antigen [39]. Although we
also observe alloantigen-speciﬁc CD8 dysfunction associated
with epithelial expression of HY in the solid tumor model,
our leukemia model suggests that epithelial expression
of alloantigen partially preserves GVL effects and PD-1
expression is insufﬁcient to produce a dysfunctional
phenotype.
Our leukemia challenge model indicates that continued
presence of PDL-1 on lymphoblastic leukemia cells produces
loss of leukemia control when the target miHA is hema-
topoietically restricted, an approach that was sufﬁcient to
reverse epithelial alloantigen-induced CD8 dysfunction in
the solid tumor model. We, therefore, contend that blockade
of PDL-1, alone or in conjunction with PD-1 blockade, would
be required to completely reverse GVL suppression in this
setting, and studies are ongoing to address this effect. Studies
of PDL-1 blockade have been limited in preclinical acute
lymphoblastic leukemia studies and represent the next
logical step in understanding this phenomenon.
Further, we demonstrate a loss of PDL-1 expression on
leukemia cells, despite ongoing expression of PD-1 onmiHA-
speciﬁc CD8, in the setting of broad antigen expression. It is
intriguing to consider whether speciﬁc signals, from allor-
eactive CD8, the local environment, or both, may be capable
of modulating PD-1/PDL-1 interactions [29,40] to abrogate
immune escape. Our observations regarding the differential
effects of alloantigen distribution, and CD8 reactivity, could
be particularly useful in identifying critical “molecular
switches” in this interaction that could be used to augment
the efﬁcacy of miHA-targeted adoptive therapy for acute
lymphoblastic leukemia while avoiding exogenous gene
modiﬁcation of T cells.
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